Alpha1 Antitrypsin Deficiency clinical trials

Explore recruiting alpha1 antitrypsin deficiency clinical trials.

Recruiting alpha1 antitrypsin deficiency studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Alpha1 Antitrypsin Deficiency trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Fazirsiran in Participants With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Austria, Germany, Portugal

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-Label, Multicenter Study to Evaluate the Long-term Safety of Weekly Intravenous Alphal-Proteinase Inhibitor (Human), Modified Process 60 mg/kg in Subjects With Pulmonary Emphysema Due to Alpha1-Antitrypsin Deficiency

Sweden, France, Finland, Estonia, Denmark, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 4, Multicenter, Double-blind, Study to Investigate the Efficacy, Safety, and Tolerability of 3 Active Doses of Respreeza® / Zemaira® Weekly Intravenous Infusions Administered over 3 Years as Longterm Maintenance Therapy in Adult Subjects with Emphysema Related to Alpha1 Antitrypsin Deficiency

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

An Open-label, Multicenter, Randomized, Non-Inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Weekly Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Patients with Alpha1-Antitrypsin Deficiency Compared to Corresponding Standard 60 mg/kg/week and 120 mg/kg/week Doses of Intravenous Alpha1-Proteinase Inhibitor (5%)

Poland, Denmark, Netherlands, Ireland, Sweden, Spain +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alpha1-Proteinase Inhibitor (Human) in Subjects with Pulmonary Emphysema due to Alpha1-Antitrypsin Deficiency

Finland, Sweden, Poland, France, Denmark

Therapeutic confirmatory (Phase III) EU CTIS Study details

Alpha1 Antitrypsin Deficiency trials by city

Alpha1 Antitrypsin Deficiency in Toronto Alpha1 Antitrypsin Deficiency in Vancouver Alpha1 Antitrypsin Deficiency in Montreal Alpha1 Antitrypsin Deficiency in Calgary Alpha1 Antitrypsin Deficiency in Edmonton Alpha1 Antitrypsin Deficiency in Ottawa Alpha1 Antitrypsin Deficiency in Winnipeg Alpha1 Antitrypsin Deficiency in Quebec City Alpha1 Antitrypsin Deficiency in Hamilton Alpha1 Antitrypsin Deficiency in Kitchener Alpha1 Antitrypsin Deficiency in London Alpha1 Antitrypsin Deficiency in Halifax Alpha1 Antitrypsin Deficiency in New York Alpha1 Antitrypsin Deficiency in Los Angeles Alpha1 Antitrypsin Deficiency in Chicago Alpha1 Antitrypsin Deficiency in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease